Mesoblast Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MESO Nasdaq 2836 www.mesoblast.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mesoblast Limited

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M - Jan 8th, 2026 4:46 pm
Mesoblast (ASX:MSB) Valuation Check as Board Revamp Supports Commercial Expansion Strategy - Jan 4th, 2026 3:14 pm
ASX Growth Leaders With Strong Insider Confidence - Jan 4th, 2026 12:38 pm
Mesoblast Announces Changes to Board of Directors' Leadership Roles - Jan 1st, 2026 4:02 pm
Sector Update: Health Care Stocks Edge Higher Premarket Tuesday - Dec 30th, 2025 7:02 am
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Fed Meeting Minutes - Dec 30th, 2025 6:47 am
Mesoblast Refinances Debt With New $125 Million Credit Facility - Dec 30th, 2025 1:40 am
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line - Dec 29th, 2025 4:57 pm
Does Mesoblast’s Volatile Surge Signal Opportunity at A$2.77 in 2025? - Dec 16th, 2025 7:07 pm
How Investors Are Reacting To Mesoblast (ASX:MSB) Remestemcel-L’s Remission Edge And FDA-Backed Niche Leadership - Dec 16th, 2025 1:08 pm
Mesoblast (ASX:MSB): Reassessing Valuation After Recent Share Price Rebound and Long-Term Return Surge - Dec 16th, 2025 10:10 am
Mesoblast (MESO) Sees Optimism From Analysts - Dec 15th, 2025 10:35 am
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD - Dec 11th, 2025 4:22 pm
Mesoblast Participation at Piper Sandler Conference - Dec 3rd, 2025 4:10 pm
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors - Dec 1st, 2025 7:00 am
3 ASX Growth Stocks With Insider Ownership Up To 38% - Nov 27th, 2025 12:38 pm
Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue - Nov 24th, 2025 4:39 pm
Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids - Nov 20th, 2025 4:32 pm
James M. O’Brien Appointed Chief Financial Officer at Mesoblast - Nov 16th, 2025 11:52 pm
Mesoblast Limited (ASX:MSB): Are Analysts Optimistic? - Nov 11th, 2025 6:58 pm